Trademark Overview
On Monday, September 25, 2023, a trademark application was filed for XARMAPSII with the United States Patent and Trademark Office. The USPTO has given the XARMAPSII trademark a serial number of 98196234. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, April 17, 2024. This trademark is owned by REGENXBIO Inc.. The XARMAPSII trademark is filed in the Pharmaceutical Products category with the following description:
Biological preparations for medical use; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; Pharmaceutical preparations for the treatment of genetic diseases and disorders and central nervous system (CNS) disorders, namely, neurodegenerative disorders; Pharmaceutical preparations for use in gene therapy; Clinical medical reagents for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders and neurodegenerative disorders; Therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; Pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of diseases, sicknesses, and disorders, namely, lysosomal storage disorders; gene therapy preparation containi...
